IL Chicago의 위암 임상 시험
위암 관련 연구 16개가 Chicago 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
피험자 모집 중관찰 연구건강한 지원자 환영
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 외 1개
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
피험자 모집 중2상
- University of Illinois Cancer Center, Chicago
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
피험자 모집 중2/3상
- Local Institution - 0379, Chicago
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
피험자 모집 중2/3상
- Illinois Cancer Specialists, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
피험자 모집 중1상
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
피험자 모집 중3상
- Research Site, Chicago
A Phase 1/1b Study of IAM1363 in HER2 Cancers
피험자 모집 중1상
- University of Chicago, Chicago
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
피험자 모집 중2상
- University of Chicago, Chicago
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
피험자 모집 중1상
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- University of Chicago Medical Center, Chicago
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
피험자 모집 중1상
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
피험자 모집 중1/2상
- University of Chicago Medical Center, Chicago
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
피험자 모집 중3상
- Northwestern University, Chicago
- University of Chicago, Chicago
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
피험자 모집 중1/2상
- University of Chicago, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Chicago
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
피험자 모집 중관찰 연구
- The University of Chicago, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
피험자 모집 중1상
- University of Chicago, Chicago
다른 도시의 위암 시험
- Houston, TX연구 42개
- Boston, MA연구 32개
- New York City, NY연구 31개
- Nashville, TN연구 28개
- Baldwin Park, CA연구 22개
- Los Angeles, CA연구 22개
- Arlington, VA연구 20개
- Dallas, TX연구 19개
- San Antonio, TX연구 19개
- Grand Rapids, MI연구 18개
- St. Louis, MO연구 18개
- Washington, DC연구 16개
Chicago의 다른 연구
- 비소세포폐암연구 61개
- 유방암연구 59개
- 암 (전체)연구 51개
- 전이성 암연구 45개
- 전립선암연구 45개
- 폐암연구 41개
- 비만연구 41개
- 난소암연구 36개
- 대장직장암연구 34개
- 뇌졸중연구 34개
- 심부전연구 31개
- 과체중연구 29개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.